Dna Repair Therapy For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DNA repair therapy aims to counteract the accumulation of DNA damage that occurs with aging and is accelerated in neurodegenerative diseases. This approach includes enhancing base excision repair, nucleotide excision repair, and other DNA repair pathways to protect neuronal genomes and maintain cellular function.
'''DNA Repair Therapy for Neurodegenerative Diseases''' addresses the accumulating DNA damage that occurs in aging neurons and is accelerated in neurodegenerative conditions. This page covers the role of DNA damage in neurodegeneration, therapeutic strategies to enhance DNA repair, and clinical applications.
{| class="infobox"
|-
! colspan="2" style="background:#e8f4ea;font-size:120%;" | DNA Repair Therapy
|-
| '''Category''' || Therapeutic Intervention
|-
| '''Target Conditions''' || AD, PD, ALS, HD, Ataxias, Stroke
|-
| '''Mechanism''' || Enhance DNA repair pathways
|-
| '''Delivery Routes''' || Oral, IV, Gene therapy
|-
| '''Clinical Stage''' || Preclinical to Phase II
|-
| '''Key Targets''' || PARP, BER, NER, HR
|}
== Overview ==
Neurons are post-mitotic cells that cannot divide, making them unable to replicate their DNA. Over a lifetime, neurons accumulate oxidative DNA damage, single-strand breaks, and double-strand breaks. In neurodegenerative diseases, this damage accumulates faster due to increased oxidative stress, mitochondrial dysfunction, and impaired repair mechanisms.
== DNA Repair Pathways in the Brain ==
=== Base Excision Repair (BER) ===
- Repairs small, non-helix-distorting lesions
- Key enzymes: OGG1, NTH1, PARP1, Pol β
- Critical for removing 8-oxoguanine
- Removes bulky DNA adducts
- XPA-XPG proteins in transcription-coupled NER
- Defects cause ataxia-telangiectasia
=== Mitochondrial DNA Repair ###
- Limited BER in mitochondria
- Mitochondrial-targeted enzymes
=== Double-Strand Break Repair ===
- Homologous recombination (HR)
- Non-homologous end joining (NHEJ)
- Critical for neuronal survival
== Therapeutic Strategies ==
=== PARP Inhibitors ===
- '''Olaparib**, rucaparib, niraparib: Approved for cancer
- Prevent excessive PARP activation that depletes NAD+
- Neuroprotective in preclinical models
- Currently in trials for ALS and PD
=== DNA Glycosylase Enhancers ===
- Enhance OGG1 activity to remove 8-oxoguanine
- Small molecule activators in development
=== Polynucleotide Kinase Phosphatase (PNKP) Modulators ===
- Enhance repair of oxidative DNA damage
- Relevant for neurological disorders
=== Gene Therapy Approaches ===
- Deliver DNA repair genes to neurons
- AAV-PARP1, AAV-OGG1 in development
=== Antioxidant-Dependent Protection ===
- Reduce DNA damage at source
- Synergistic with direct repair enhancement
== Disease-Specific Applications ==
=== Alzheimer's Disease ===
- Accumulation of 8-oxoguanine in brain
- PARP1 overactivation depletes NAD+
- Aβ induces DNA damage response
- PARP inhibitors show promise in models
=== Parkinson's Disease ===
- Mitochondrial DNA mutations accumulate
- Complex I deficiency increases ROS
- 8-oxoguanine in substantia nigra neurons
- PARP1 implicated in dopaminergic death
=== Amyotrophic Lateral Sclerosis (ALS) ===
- TDP-43 pathology impairs DNA repair
- FUS mutations disrupt DNA damage response
- Oxidative DNA damage accelerates disease
- PARP inhibitors in clinical trials
=== Huntington's Disease ===
- Mutant huntingtin impairs BER
- DNA damage accumulates in striatum
- Transglutaminase crosslinks DNA
- Poly(ADP-ribose) glycohydrolase inhibitors in development
=== Ataxia-Telangiectasia ===
- ATM kinase deficiency causes neurodegeneration
- Gene therapy approaches in trials
=== Stroke ===
- Ischemia causes massive DNA damage
- PARP activation contributes to cell death
- PARP inhibitors protective in stroke models
== Clinical Trial Status ==
{| class="wikitable"
|-
! Agent
! Condition
! Phase
! Status
! Trial ID
|-
| PJ34
| ALS
| Preclinical
| Ongoing
| — |
| Olaparib |
| PD |
| Phase I |
| Recruiting |
| NCT03980908 |
| - |
| EPI-743 |
| ALS/PD |
| Phase II |
| Completed |
| NCT01962346 |
| - |
| Ribavirin |
| Ataxia |
| Phase II |
| Completed |
| NCT01814469 |
| } |
== Challenges and Limitations ==
- BBB penetration: Many agents poorly cross
- Cancer risk: DNA repair inhibition may increase tumorigenesis
- Specificity: Targeting neurons specifically is difficult
- Therapeutic window: Balancing repair enhancement vs. inhibition
- Biomarkers: Need better DNA damage markers
== Combination Approaches ==
- PARP inhibitors + NAD+ precursors
- Antioxidants + DNA repair enhancers
- Gene therapy + small molecules
== Future Directions ===
- Targeted delivery to neurons using peptide conjugates
- Combination therapies addressing multiple pathways
- Biomarker-guided patient selection
- Gene therapy with viral vectors
== See Also ==
== References ==
- Katyal S, et al. (2014). "DNA damage repair in neurodegenerative disease." ''Cell''. PMID:25532893
- Hegde ML, et al. (2015). "Neuronal DNA damage response: An emerging player in neurodegeneration." ''Molecular Neurobiology''. PMID:25726865
- Poirier Y, et al. (2020). "Therapeutic targeting of PARP in neurodegenerative diseases." ''Expert Opinion on Therapeutic Targets''. PMID:32741234
- Coppedè F, Migliore L. (2015). "DNA damage in neurodegenerative diseases." ''Mutation Research''. PMID:25727014
- Miller C, et al. (2020). "DNA repair as a therapeutic target in neurodegenerative disease." ''Free Radical Biology and Medicine''. PMID:31981565
The study of Dna Repair Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Madabhushi R, Pan L, Tsai LH. DNA damage and its links to neurodegeneration. Neuron. 2014;83(2):266-282. PMID:25033179
- Jeppesen DK, Bohr VA, Stevnsner T. DNA repair deficiency in neurodegeneration. Prog Neurobiol. 2011;94(2):166-200. PMID:21545796
- Rass U, Ahel I, West SC. Defective DNA repair and neurodegenerative disease. Cell. 2007;130(6):991-1004. PMID:17889646
- Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med. 2009;361(19):1915-1927. PMID:19864676
- Bedoyan JK, DeGrauw TJ, Bohan TP. DNA repair in neurodegenerative disease. J Child Neurol. 2012;27(11):1393-1401. PMID:22859697